Since the early 1990s, when Roberts and Szabos cytoprotection concept had already been more than one decade old, but still not implemented in therapy, we suggest the stable gastric pentadecapeptide BPC 157 as the most relevant mediator of the cytoprotection concept.
The FDA approved a different formulation of Semaglutide GLP-1, marketed as Wegovy, which is explicitly designed for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes
Understanding Eligibility for Ozempic Medical Weight Loss: Who Is Not a Good Candidate
Key takeaways Zepbound and Wegovy are both FDA-approved weight loss injections
The FDA prohibits its sale or use as a drug, supplement, or treatment in humans
from the University of Arizona